Return to site

Liberty Biopharma Complete Acquisition of Cloud Medical Group

Richmond, British Columbia - Liberty Biopharma Inc. (“Liberty Biopharma” or the “Company”) (TSXV: LTY) is pleased to announce the completion of the share exchange transaction (the “Transaction”) with Cloud Medical Group Inc. (“CMGI”) and receipt of final approval from the TSX Venture Exchange ("TSXV"), as previously announced on December 21, 2017.

“Liberty Biopharma is extremely important in the advancement of our business as a global leader in developing cell therapy and e-healthcare solutions, by increasingly deploying artificial intelligence-augmented applications,” stated Bruno Wu, Founder of Cloud Medical Group Inc.. “We are well positioned to launch new business projects in precision medicine, personalized epigenetic solutions, genomic sequencing and data management, and super intelligence driven healthcare related asset securitization.”

About Liberty Biopharma Inc.

Liberty Biopharma is a clinical stage biopharmaceutical company developing and commercializing regenerative stem cell technologies and therapeutic solutions for independence and quality of life. The Company’s focus is on significant areas of unmet clinical need, such as wound management, osteoarthritis, musculoskeletal injury, cardiovascular diseases, and autoimmune diseases.

About Cloud Medical Group Inc.

Cloud Medical Group Inc. is a healthcare company focused on the delivery of cell therapy and e-healthcare solutions, increasingly deploying artificial intelligence-augmented applications. Initial areas of focus include i) preventative medicine, ii) dynamic oncology-based data analysis, iii) genetic analysis, and iv) insurance and financial payment for healthcare using next-generation artificial intelligence and blockchain-powered technology.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Liberty Biopharma may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Liberty Biopharma. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Liberty Biopharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information, please contact:

Liberty Biopharma Inc.

Alan Tam, CPA, CA

Chief Financial Officer

Telephone: (604) 604-377-7575

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly